在帕金森病中神经和神经递质平衡的素
Alagudurai Krishnamoorthy1, Riddhi Upadhyay2, Murugan Sevanan2
1International Institute of Biotechnology and Toxicology, Padappai, Chennai, India.
Methods in molecular biology (Clifton, N.J.)
|March 1, 2024
概括
氨酸是一种黄类化合物,有效地恢复多巴胺水平和MPTP诱导的帕金森病的神经营养因子.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 1-甲基-4--1,2,3,6-四甲 (MPTP) 诱导帕金森病 (PD) 通过准黑色物质的多巴胺基神经元 (SNpc) 和状体 (ST) 的多巴胺水平来诱导帕金森病 (PD).
- 神经营养因子的稳定性受损,包括来自大脑的神经营养因子 (BDNF),与多巴胺基神经元缩和多巴胺降解有关.
- 素是一种黄类化合物,表现出药理学潜力,可以影响神经营养因素和神经递质.
研究的目的:
- 在MPTP诱导的帕金森病小鼠模型中研究辛对神经递质和神经营养因子水平的影响.
- 分析素在恢复多巴胺,其代谢物 (DOPAC,HVA) 和神经营养因子 (BDNF,GDNF) 的稳定性中的作用.
主要方法:
- 使用高性能液体色谱 (HPLC) 来量化SNPc和ST区域的多巴胺,3,4-二基酸 (DOPAC) 和同酸 (HVA) 水平.
- 基因表达分析,特别是逆转录聚合酶链反应 (RT-PCR),用于检查BDNF和质衍生神经营养因子 (GDNF) 的水平.
- 这些分析是在接受MPTP诱导的急性帕金森病的小鼠的大脑组织上进行的.
主要成果:
- 观察到,在接受MPTP治疗的小鼠中,施用素可以平衡多巴胺及其代谢物 (DOPAC,HVA) 的变化水平.
- 该研究证实了BDNF和GDNF在维持多巴胺,DOPAC和HVA的平衡中发挥着重要的作用.
- 氨酸表现出调节神经递质和神经营养因子水平的能力.
结论:
- 氨酸通过恢复神经递质平衡和神经营养因子平衡在帕金森病小鼠模型中表现出神经保护作用.
- 这些发现表明,辛具有作为帕金森病治疗剂的潜力,向关键分子途径参与神经退行.
相关概念视频
Parkinson's Disease: Overview
544
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
544
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Excitatory and Inhibitory Effects of Neurotransmitters
10.0K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
10.0K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
673
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
673


